Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Pharmacokinetics and Safety of Cadazolid in Patients With Clostridium Difficile Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent prior to any study-mandated procedure.~* Non-pregnant females were to remain non-pregnant for 1 month after the end of the study. Female subjects of child-bearing potential must have had a negative serum pregnancy test at screening and must have used a reliable method of contraception~* Subjects with severe CDAD; Clostridium difficile infection (CDI) must have been microbiologically proven, using a validated enzyme-linked immunosorbent assay (ELISA) for the detection of C. difficile toxin A (TcdA) and/or C. difficile toxin B (TcdB). The severity of CDAD was assessed according to the current European Union guidelines - European Society of Clinical Microbiology and Infectious Diseases (ESCMID).~* Received oral vancomycin or oral/intravenous (i.v.) metronidazole therapy for the treatment of CDAD.~* Ability to communicate well with the investigator in the local language, and to understand and comply with the requirements of the study.~Exclusion Criteria:~* Known hypersensitivity to any excipients of the drug formulation.~* Clinical evidence of any relevant disease other than CDAD and/or existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism or excretion of the study drug.~* Veins unsuitable for i.v. puncture on either arm (e.g., veins that are difficult to locate, access, or puncture; veins with a tendency to rupture during or after puncture).~* Subjects with rare hereditary fructose intolerance, glucose-galactose malabsorption, saccharase-isomaltase deficiency or previously undiagnosed diabetes mellitus.~* Subjects who have a life-threatening condition, which may be related to CDAD or other underlying illness.~* Any clinically relevant electrocardiogram (ECG) abnormality at screening.~* Subjects who were unable to swallow or have difficulty swallowing.~* Subjects with vomiting, ileus or not passing stool.~* Likelihood of death within 72 hours from any cause.~* Life-threatening or fulminant CDAD (White blood cell count \> 30 × 10\^9/L; temperature \> 40 °C; or septic shock, peritoneal signs or significant dehydration).~* History of ulcerative colitis or Crohn's disease.~* Loss of 250 mL or more of blood within 3 months prior to screening.~* Positive results from the hepatitis serology, except for vaccinated subjects, at screening.~* Positive results from the human immunodeficiency virus (HIV) serology at screening.~* Legal incapacity or limited legal capacity at screening.~* Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Cadazolid (Type: EXPERIMENTAL): Single oral dose of 3000 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).